Mendus
Clinical-stage company developing immunotherapies to prevent tumor recurrence.
IMMU | ST
Overview
Corporate Details
- ISIN(s):
- SE0005003654 (+1 more)
- LEI:
- 529900AFBGFR7ZB50J95
- Country:
- Sweden
- Address:
- Västra Trädgårdsgatan 15, 111 53 Stockholm
- Website:
- https://mendus.com/
- Sector:
- Manufacturing
Description
Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-07 08:00 |
Immunicum AB (publ) Receives FDA Fast Track Designation for Ilixadencel in Gast…
|
English | PDF • 108.6 KB | ||
| 2020-12-07 08:00 |
Immunicum AB (publ) erhåller Fast Track Designation från FDA för ilixadencel fö…
|
Swedish | PDF • 91.1 KB | ||
| 2020-11-18 23:35 |
Notice of Extraordinary General Meeting in Immunicum AB (publ)
|
Swedish | PDF • 127.3 KB | ||
| 2020-11-18 23:35 |
Notice of Extraordinary General Meeting in Immunicum AB (publ)
|
English | PDF • 136.7 KB | ||
| 2020-11-18 23:30 |
Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cance…
|
English | PDF • 166.3 KB | ||
| 2020-11-18 23:30 |
Immunicum och DCprime går samman för att skapa ett ledande bolag inom cellbaser…
|
Swedish | PDF • 140.4 KB | ||
| 2020-11-10 13:30 |
Appointment to the Nomination Committee for Immunicum AB (publ)
|
English | PDF • 66.7 KB | ||
| 2020-11-10 13:30 |
Komplettering av valberedning i Immunicum AB (publ)
|
Swedish | PDF • 61.2 KB | ||
| 2020-11-05 08:00 | Swedish | PDF • 1002.3 KB | |||
| 2020-11-05 08:00 | English | PDF • 1001.5 KB | |||
| 2020-11-04 13:30 |
Nomination Committee Appointed for the Annual General Meeting 2021 in Immunicum…
|
English | PDF • 62.2 KB | ||
| 2020-11-04 13:30 |
Valberedning utsedd inför årsstämman 2021 i Immunicum AB (publ)
|
Swedish | PDF • 61.6 KB | ||
| 2020-10-29 08:00 |
Magnus Persson lämnar styrelsen i Immunicum AB (publ)
|
Swedish | PDF • 109.4 KB | ||
| 2020-10-29 08:00 |
Magnus Persson to Resign from Immunicum’s Board of Directors
|
English | PDF • 104.7 KB | ||
| 2020-09-30 18:00 |
Immunicum AB Announces Update on Corporate and Clinical Development Strategy
|
English | PDF • 106.8 KB |
Automate Your Workflow. Get a real-time feed of all Mendus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mendus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mendus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-11 | Erik Manting | Other | Buy | 7,780 | 56,249.40 SEK |
| 2025-03-11 | Erik Manting | Other | Buy | 7,780 | 55,704.80 SEK |
| 2025-02-25 | Sven Arne Andreasson | Other | Buy | 25,000 | 198,750.00 SEK |
| 2024-04-02 | Erik Manting | Other | Other | 885,648 | 425,111.04 SEK |
| 2024-04-02 | Dharminder Chahal | Other | Other | 882,048 | 423,383.04 SEK |
| 2024-04-02 | Leopold Bertea | Other | Other | 267,858 | 128,571.84 SEK |
| 2022-10-25 | Sven Arne Andreasson | Other | Sell | 15,000 | 31,950.00 SEK |
| 2022-10-12 | Sven Arne Andreasson | Other | Sell | 10,000 | 18,800.00 SEK |
| 2022-05-20 | Erik Manting | Other | Buy | 37,059 | 86,347.47 SEK |
| 2022-05-19 | Ann-Charlotte Ferm | Other | Buy | 100,000 | 215,900.00 SEK |
Peer Companies
